• Daniel Bruynseels, Cristina Solomon, Angela Hallam, Peter W Collins, Rachel E Collis, Vincent Hamlyn, and Judith E Hall.
• Department of Anaesthetics and Pain Control, Cardiff and Vale University Health Board, Cardiff, UK.
• J Emerg Med. 2016 Jan 1; 50 (1): 104-7.e1.

BackgroundThe gold standard of trial design is the double-blind, placebo-controlled, randomized trial. Intravenous medication, which needs reconstitution by the attending clinician in an emergency situation, can be challenging to incorporate into a suitably blinded study.DiscussionWe have developed a method of blindly reconstituting and administering fibrinogen concentrate (presented as a lyophilized powder), where the placebo is normal saline. Fibrinogen concentrate is increasingly being used early in the treatment of major hemorrhage. Our methodology was designed for a multicenter study investigating the role of fibrinogen concentrate in the treatment of the coagulopathy associated with major obstetric hemorrhage. The method has been verified by a stand-alone pharmaceutical manufacturing unit with an investigational medicinal products license, and to date has successfully been applied 45 times in four study centers. There have been no difficulties in reconstitution and no related adverse events reported.ConclusionWe feel our method is simple to perform and maintains blinding throughout, making it potentially suitable for use in other trials conducted in psychologically high-pressure environments. Although fibrinogen concentrate was the focus of our study, it is likely that the method is applicable to other lyophilized medication with limited shelf life (e.g., antibiotics).Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…